NKF Spring Clinical Meetings 2024
Advertisement
Cesia Portillo discussed her poster on creating a roadmap for APOL1-mediated kidney disease (AMKD).
Suzanne Watnick shared thoughts on the Shaul G. Massry lectureship, COVID-19, kidney transplantation, and policy issues.
A. Ersin Yassa and Yasemin Balin were the winners of the inaugural Neph Madness tournament.
Martin Pollak reflected on winning the David M. Hume Memorial Award and on breakthroughs in glomerular diseases.
Sylvia Rosas shared highlights from her term as president of the National Kidney Foundation.
Bhupinder Singh and Stewart Turner discussed serum bicarbonate concentrations in patients with CKD and metabolic acidosis.
Michael Spigler of American Kidney Fund discussed its work and its findings on education level and transplant discussions.
Areef Ishani spoke about his abstract on renal outcomes with chlorthalidone versus hydrochlorothiazide for hypertension.
Dr. Chee Kay Cheung discussed two presentations on IgA nephropathy findings from the SPARTAN and PROTECT studies.
Editorial board member Joel Topf reflects on the NKF Spring Clinical Meetings and the value of #NephTwitter.
Dr. Robert Montgomery spoke about advances in xenotransplantation, including the pig kidney transplant he recently performed.
Dr. Dana Rizk discussed her APPLAUSE-IgAN study findings on iptacopan versus placebo for IgA nephropathy.
Dr. Mohamed G. Atta discussed the importance of educating clinicians about Fabry disease.
Ajay K. Singh discussed his findings on daprodustat dosing and utilization of finerenone.
Changes to the ordering plan could help optimize the use of SZC to treat acute hyperkalemia.
Nocturnal hypertension is common in CKD, but it was unclear if renal denervation could lower nighttime blood pressure.
A patient may have normal creatinine and complements but still have highly active lupus nephritis requiring therapy.
Severe hyperkalemia after adrenalectomy is rare but can be managed medically with sodium zirconium cyclosilicate (SZC).
Sparsentan demonstrated meaningful benefits for preservation of kidney function compared with irbesartan over 2 years.
Dose adjustment requirements may differ between ESA-hyporesponsive and non–ESA-HR patients receiving daprodustat.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.